Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

Figure 4

Knockdown of Nrf2 in K562/G01 cells increased the ROS level.